OMOP 2011 Symposium Presentations

OMOP 2011 Symposium Agenda

2010-11 Experiment Results

Review of the OMOP Experiment
Marc Overhage, MD, PhD, Director, Medical Informatics and Research Scientist, Regenstrief Institute, Inc., Regenstrief Professor of Medical Informatics, Indiana University School of Medicine; CEO and President Indiana Health Information Exchange; OMOP Research Investigator

Click on the play button to start the audio and slide presentation.

Method Performance Results from the Health Outcomes of Interest Experiment - Part 1
Patrick Ryan, MEng, Associate Director, Analytical Epidemiology, Johnson & Johnson Pharmaceutical R&D, OMOP Research Investigator
David Madigan, PhD, Professor, Columbia University, OMOP Research Investigator

Click on the play button to start the audio and slide presentation.

Method Performance Results from the Health Outcomes of Interest Experiment - Part 2

Click on the play button to start the audio and slide presentation.

Lessons Learned from Systematic Observational Analysis
Standardized Tools for Data Characterization and Utility of Exploratory Visualization
Paul Stang, PhD, Senior Director, Epidemiology, Johnson & Johnson Pharmaceutical Research and Development, OMOP Research Investigator

Click on the play button to start the audio and slide presentation.

Managing Data Quality for an Active Surveillance System
Christian Reich, MD, PhD, Program Director OMOP

Click on the play button to start the audio and slide presentation.

Implications of Health Outcomes of Interest Definitions – Acute Liver Injury Case Study
Judith A. Racoosin, MD, MPH, Sentinel Initiative Scientific Lead, FDA; OMOP Research Investigator

Click on the play button to start the audio and slide presentation.

Future Research and Applications Beyond Drug Safety Signal Refinement
Opportunities for Signal Detection in an Active Surveillance System
Andrew Bate, PhD, Pfizer Inc., Senior Director, Analytics Team Lead, Epidemiology, Worldwide Safety Strategy

OMOP Methods Application for Comparative Effectiveness
Jesse Berlin, ScD, Johnson & Johnson Pharmaceutical R & D, Vice President, Epidemiology

OMOP’s Future
Thomas P. Scarnecchia, MS, Executive Director OMOP

Background Materials / Handouts 2011 Symposium